About Neogenin
Neogenin (NEO1) is a protein
from Homo sapiens identified by UniProt accession
Q92859, 1461 residues long.
MolForge cross-references it against 0 known binders and
138 disease associations.
Target properties
| Protein name | Neogenin |
|---|
| UniProt accession | Q92859 |
|---|
| Gene | NEO1 |
|---|
| Organism | Homo sapiens |
|---|
| Length | 1461 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (138)
Diseases linked to this target (Open Targets).
- body fat percentage · score 0.45
- Red cell distribution width · score 0.45
- cortical thickness · score 0.37
- appendicular lean mass · score 0.37
- blood protein measurement · score 0.36
- self reported educational attainment · score 0.35
- dentures · score 0.35
- mean corpuscular volume · score 0.35
- urate measurement · score 0.35
- brain measurement · score 0.35
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-Q92859-F1 | alphafold | PREDICTED | 67.98 | — |
Amino-acid sequence (1461 residues)
MAAERGARRL LSTPSFWLYC LLLLGRRAPG AAAARSGSAP QSPGASIRTF TPFYFLVEPV DTLSVRGSSV ILNCSAYSEP SPKIEWKKDG TFLNLVSDDR RQLLPDGSLF ISNVVHSKHN KPDEGYYQCV ATVESLGTII SRTAKLIVAG LPRFTSQPEP SSVYAGNNAI LNCEVNADLV PFVRWEQNRQ PLLLDDRVIK LPSGMLVISN ATEGDGGLYR CVVESGGPPK YSDEVELKVL PDPEVISDLV FLKQPSPLVR VIGQDVVLPC VASGLPTPTI KWMKNEEALD TESSERLVLL AGGSLEISDV TEDDAGTYFC IADNGNETIE AQAELTVQAQ PEFLKQPTNI YAHESMDIVF ECEVTGKPTP TVKWVKNGDM VIPSDYFKIV KEHNLQVLGL VKSDEGFYQC IAENDVGNAQ AGAQLIILEH APATTGPLPS APRDVVASLV STRFIKLTWR TPASDPHGDN LTYSVFYTKE GIARERVENT SHPGEMQVTI QNLMPATVYI FRVMAQNKHG SGESSAPLRV ETQPEVQLPG PAPNLRAYAA SPTSITVTWE TPVSGNGEIQ NYKLYYMEKG TDKEQDVDVS SHSYTINGLK KYTEYSFRVV AYNKHGPGVS TPDVAVRTLS DVPSAAPQNL SLEVRNSKSI MIHWQPPAPA TQNGQITGYK IRYRKASRKS DVTETLVSGT QLSQLIEGLD RGTEYNFRVA ALTINGTGPA TDWLSAETFE SDLDETRVPE VPSSLHVRPL VTSIVVSWTP PENQNIVVRG YAIGYGIGSP HAQTIKVDYK QRYYTIENLD PSSHYVITLK AFNNVGEGIP LYESAVTRPH TDTSEVDLFV INAPYTPVPD PTPMMPPVGV QASILSHDTI RITWADNSLP KHQKITDSRY YTVRWKTNIP ANTKYKNANA TTLSYLVTGL KPNTLYEFSV MVTKGRRSST WSMTAHGTTF ELVPTSPPKD VTVVSKEGKP KTIIVNWQPP SEANGKITGY IIYYSTDVNA EIHDWVIEPV VGNRLTHQIQ ELTLDTPYYF KIQARNSKGM GPMSEAVQFR TPKADSSDKM PNDQASGSGG KGSRLPDLGS DYKPPMSGSN SPHGSPTSPL DSNMLLVIIV SVGVITIVVV VIIAVFCTRR TTSHQKKKRA ACKSVNGSHK YKGNSKDVKP PDLWIHHERL ELKPIDKSPD PNPIMTDTPI PRNSQDITPV DNSMDSNIHQ RRNSYRGHES EDSMSTLAGR RGMRPKMMMP FDSQPPQPVI SAHPIHSLDN PHHHFHSSSL ASPARSHLYH PGSPWPIGTS MSLSDRANST ESVRNTPSTD TMPASSSQTC CTDHQDPEGA TSSSYLASSQ EEDSGQSLPT AHVRPSHPLK SFAVPAIPPP GPPTYDPALP STPLLSQQAL NHHIHSVKTA SIGTLGRSRP PMPVVVPSAP EVQETTRMLE DSESSYEPDE LTKEMAHLEG LMKDLNAITT A
Explore Neogenin with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets